Aeterna Zentaris (AEZS) Stock Price, News & Analysis

0.00 (0.00%)
(As of 03:03 PM ET)
Today's Range
50-Day Range
52-Week Range
1,343 shs
Average Volume
15,881 shs
Market Capitalization
$9.57 million
P/E Ratio
Dividend Yield
Price Target

Aeterna Zentaris MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
661.4% Upside
$15.00 Price Target
Short Interest
0.45% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.79 out of 5 stars

AEZS stock logo

About Aeterna Zentaris Stock (NASDAQ:AEZS)

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

AEZS Stock Price History

AEZS Stock News Headlines

Aeterna Zentaris (NASDAQ:AEZS) Now Covered by Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
AEterna Zentaris: Q4 Earnings Insights
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
Aeterna Zentaris Inc.
AEterna Zentaris Inc AEZS
Aeterna Zentaris GAAP EPS of -$0.85
Closing Bell: Aeterna Zentaris Inc down on Monday (AEZS)
Closing Bell: Aeterna Zentaris Inc flat on Tuesday (AEZS)
H.C. Wainwright Keeps Their Buy Rating on Aeterna Zentaris (AEZS)
See More Headlines
Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$4.50 million
Book Value
$3.75 per share


Free Float
Market Cap
$9.57 million
No Data

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Klaus Paulini Ph.D.
    President, CEO & Executive Director
  • Mr. Giuliano La Fratta
    Senior VP of Finance & CFO
  • Dr. Michael Teifel Ph.D.
    Senior VP of Non-Clinical Development & Chief Scientific Officer
  • Dr. Nicola Ammer M.D.
    Chief Medical Officer & Senior VP of Clinical Development
  • Dr. Matthias Gerlach
    Senior Vice President Manufacturing & Supply Chain

AEZS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings
or view top-rated stocks.

What is Aeterna Zentaris' stock price target for 2024?

1 brokerages have issued 1-year price objectives for Aeterna Zentaris' stock. Their AEZS share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 661.4% from the stock's current price.
View analysts price targets for AEZS
or view top-rated stocks among Wall Street analysts.

How have AEZS shares performed in 2024?

Aeterna Zentaris' stock was trading at $1.86 at the beginning of 2024. Since then, AEZS stock has increased by 5.9% and is now trading at $1.97.
View the best growth stocks for 2024 here

Are investors shorting Aeterna Zentaris?

Aeterna Zentaris saw a drop in short interest in March. As of March 31st, there was short interest totaling 21,700 shares, a drop of 25.7% from the March 15th total of 29,200 shares. Based on an average daily trading volume, of 17,300 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.5% of the shares of the stock are short sold.
View Aeterna Zentaris' Short Interest

When is Aeterna Zentaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AEZS earnings forecast

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) announced its quarterly earnings results on Wednesday, March, 27th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by $0.19. The biopharmaceutical company earned $0.12 million during the quarter. Aeterna Zentaris had a negative net margin of 368.01% and a negative trailing twelve-month return on equity of 63.20%.

When did Aeterna Zentaris' stock split?

Aeterna Zentaris's stock reverse split before market open on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?
How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AEZS) was last updated on 4/24/2024 by Staff

From Our Partners